MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 534666 | Name: MR 2266

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MR 2266 is a narcotic antagonist.

Chemical Structure

MR 2266
MR 2266
CAS#56649-76-4

Theoretical Analysis

MedKoo Cat#: 534666

Name: MR 2266

CAS#: 56649-76-4

Chemical Formula: C21H27NO2

Exact Mass: 325.2042

Molecular Weight: 325.45

Elemental Analysis: C, 77.50; H, 8.36; N, 4.30; O, 9.83

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
MR 2266; MR-2266; MR2266
IUPAC/Chemical Name
2,6-Methano-3-benzazocin-8-ol, 6,11-diethyl-3-(3-furanylmethyl)-1,2,3,4,5,6-hexahydro-, (2R,6R,11R)-
InChi Key
HEYXXBUDMDVUNQ-CEWLAPEOSA-N
InChi Code
InChI=1S/C21H27NO2/c1-3-18-20-11-16-5-6-17(23)12-19(16)21(18,4-2)8-9-22(20)13-15-7-10-24-14-15/h5-7,10,12,14,18,20,23H,3-4,8-9,11,13H2,1-2H3/t18-,20+,21+/m0/s1
SMILES Code
OC1=CC=C2C([C@]3(CC)CCN(CC4=COC=C4)[C@]([C@@H]3CC)([H])C2)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 325.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bansinath M, Ramabadran K, Turndorf H, Puig MM. Effects of the benzomorphan kappa-opiate, MR 2266 and its (+) enantiomer MR 2267, on thermonociceptive reactions in different strains of mice. Neurosci Lett. 1990 Sep 4;117(1-2):212-7. doi: 10.1016/0304-3940(90)90146-z. PMID: 1963214. 2: Bauer U, Nakazi M, Kathmann M, Göthert M, Schlicker E. The stereoselective kappa-opioid receptor antagonist Mr 2266 does not exhibit stereoselectivity as an antagonist at the orphan opioid (ORL1) receptor. Naunyn Schmiedebergs Arch Pharmacol. 1999 Jan;359(1):17-20. doi: 10.1007/pl00005317. PMID: 9933145. 3: Sandi C, Borrell J, Guaza C. Effects of the kappa opioid receptor antagonist MR-2266-BS on the acquisition of ethanol preference. Life Sci. 1990;46(16):1119-29. doi: 10.1016/0024-3205(90)90448-z. PMID: 2160572. 4: Frey HH. Effect of mu- and kappa-opioid agonists on the electroconvulsive seizure threshold in mice and antagonism by naloxone and MR 2266. Pharmacol Toxicol. 1988 Mar;62(3):150-4. doi: 10.1111/j.1600-0773.1988.tb01863.x. PMID: 2836842. 5: Xu RK, Chen L, Li H, Yang SJ, Huang XY. [Effects of kappa-opiate receptor antagonist MR-2266-BS on ACTH and prolactin release]. Sheng Li Xue Bao. 1989 Aug;41(4):395-401. Chinese. PMID: 2557673. 6: Nabeshima T, Hiramatsu M, Kameyama T. Phencyclidine-induced stereotyped behaviors after injection of ethylketocyclazocine, Mr 2266 and naltrexone in rats. Brain Res. 1986 Jul 23;378(2):234-9. doi: 10.1016/0006-8993(86)90926-1. PMID: 3015356. 7: Ramabadran K, Bansinath M, Turndorf H, Puig MM. Effects of naloxone and Mr 2266 on thermonociceptive reactions in diabetic mice. NIDA Res Monogr. 1989;95:528-9. PMID: 2561849. 8: Laorden ML, Carrillo E, Puig MM. Prevention of hyperthermia-induced convulsions in immature rat by MR-2266, a kappa antagonist. Methods Find Exp Clin Pharmacol. 1991 Nov;13(9):605-8. PMID: 1686291. 9: Sandrini M, Romualdi P, Vitale G, Morelli G, Capobianco A, Pini LA, Candeletti S. The effect of a paracetamol and morphine combination on dynorphin A levels in the rat brain. Biochem Pharmacol. 2001 Jun 1;61(11):1409-16. doi: 10.1016/s0006-2952(01)00623-2. PMID: 11331077. 10: Prokudina ES, Maslov LN, Naryzhnaya NV, Tsibulnikov SY, Lishmanov YB, Madias JE, Oeltgen PR. Cardioprotective properties of opioid receptor agonists in rats with stress-induced cardiac injury. Physiol Res. 2019 Jun 30;68(3):375-384. doi: 10.33549/physiolres.933946. Epub 2019 Mar 22. PMID: 30904005. 11: Sandrini M, Romualdi P, Capobianco A, Vitale G, Morelli G, Pini LA, Candeletti S. The effect of paracetamol on nociception and dynorphin A levels in the rat brain. Neuropeptides. 2001 Apr;35(2):110-6. doi: 10.1054/npep.2001.0852. PMID: 11384206. 12: Rabkin SW. Endogenous kappa opioids mediate the action of brain angiotensin II to increase blood pressure. Neuropeptides. 2007 Dec;41(6):411-9. doi: 10.1016/j.npep.2007.09.003. Epub 2007 Nov 5. PMID: 17980907. 13: Jackisch R, Geppert M, Illes P. Characterization of opioid receptors modulating noradrenaline release in the hippocampus of the rabbit. J Neurochem. 1986 Jun;46(6):1802-10. doi: 10.1111/j.1471-4159.1986.tb08499.x. PMID: 2871130. 14: Vonvoigtlander PF, Lahti RA, Ludens JH. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist. J Pharmacol Exp Ther. 1983 Jan;224(1):7-12. PMID: 6129321. 15: Radulović J, Janković BD. Opposing activities of brain opioid receptors in the regulation of humoral and cell-mediated immune responses in the rat. Brain Res. 1994 Oct 24;661(1-2):189-95. doi: 10.1016/0006-8993(94)91196-7. PMID: 7834369. 16: Kenakin T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol. 2004 Jan;65(1):2-11. doi: 10.1124/mol.65.1.2. PMID: 14722230. 17: Bhargava HN, Kremer EK, Gibbons MO, Philips BJ, Driver JW, Chou M. Stereospecific effects of a kappa-opiate antagonist on the actions of morphine in morphine-tolerant rats. Eur J Pharmacol. 1989 Dec 7;173(2-3):159-64. doi: 10.1016/0014-2999(89)90513-x. PMID: 2560431. 18: Stockhaus K, Ensinger HA, Gaida W, Jennewein HM, Merz H. Mr 2033 CL--a novel non-morphine-like opioid analgesic. NIDA Res Monogr. 1983 Apr;43:144-9. PMID: 6135993. 19: Ben-Sreti MM, Sewell RD, Upton N. Some observations on the effects of enantiomers of two benzomorphan narcotic antagonists and atropine on analgesia, tremor and hypothermia produced by oxotremorine. Arch Int Pharmacodyn Ther. 1982 Apr;256(2):219-27. PMID: 7103612. 20: Oka T, Negishi K, Kajiwara M, Watanabe Y, Ishizuka Y, Matsumiya T. The choice of opiate receptor subtype by neo-endorphins. Eur J Pharmacol. 1982 Apr 23;79(3-4):301-5. doi: 10.1016/0014-2999(82)90636-7. PMID: 6284522.

View History

DNP-PEG12-NHS ester

DNP-PEG12-NHS ester

Featured